| Members |
targetComponentId |
| Megarectum |
Acquired megacolon |
| Meglumin iotroxinate |
Product containing iotroxic acid (medicinal product) |
| Meglumine iothalamate 60% infusion solution vial |
Iothalamate only product |
| Melanocytic nevus - category |
Pigmented nevus |
| Melanoma in situ by body site |
Melanoma in situ |
| Melanoma vaccine |
Vaccine product |
| Melanoma vaccine |
Vaccine product |
| Melanoma: [skin] or [malignant] |
Malignant melanoma |
| Melanoma: [skin] or [malignant] |
Malignant melanoma |
| Melanotic neuroectodermal tumor of infancy |
Melanotic neuroectodermal tumor of infancy |
| Melasian type |
Melasian type |
| Memantine 2mg/mL oral solution |
Memantine hydrochloride 2 mg/mL oral solution |
| Membrane metallo-endopeptidase |
Lymphocyte antigen CD10 |
| Memory disturbance (& amnesia (& symptom)) |
Memory impairment (finding) |
| Memory impairment |
Memory impairment (finding) |
| Meningeal neoplasm, uncertain whether benign or malignant |
Meningioma of uncertain behavior (morphologic abnormality) |
| Meningioma, benign, no International Classification of Diseases for Oncology subtype |
Benign meningioma |
| Meningococcal antibody |
Antibody to Neisseria meningitidis (substance) |
| Meningococcal polysaccharide vaccine adverse reaction |
Adverse reaction to meningococcal vaccine |
| Meniscus derangement NOS |
Derangement of meniscus |
| Meniscus derangement NOS |
Derangement of meniscus |
| Menopausal &/or postmenopausal disorders |
Disorder associated with menstruation AND/OR menopause |
| Menopausal and postmenopausal disorders |
Disorder associated with menstruation AND/OR menopause |
| Menopausal and postmenopausal disorders |
Disorder associated with menstruation AND/OR menopause |
| Menstrual molimen |
Premenstrual tension syndrome |
| Menstruation disorder NOS |
Disorder of menstruation (disorder) |
| Menstruation disorder NOS |
Disorder of menstruation (disorder) |
| Menstruation disorder NOS |
Disorder of menstruation (disorder) |
| Mental &/or developmental handicap screen |
Screening for developmental disorder (procedure) |
| Mental &/or developmental handicap screen |
Screening for developmental disorder (procedure) |
| Mental disorder - unspecified whether during pregnancy or the puerperium |
Mental disorders during pregnancy, childbirth and the puerperium |
| Mental disorder during pregnancy, childbirth or the puerperium NOS |
Mental disorders during pregnancy, childbirth and the puerperium |
| Mental disorders NOS |
Mental disorder |
| Mental disorders NOS |
Mental disorder |
| Mental disorders NOS |
Mental disorder |
| Mental disorders NOS |
Mental disorder |
| Mental handicap |
Intellectual disability |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap psychiatry department |
Intellectual disability psychiatry department (environment) |
| Mental handicap psychiatry service |
Intellectual disability psychiatry service |
| Mental health annual physical examination done |
Annual physical examination for people with mental illness completed |
| Mental health crisis plan |
Mental health crisis plan |
| Mental health personal health plan |
Mental health personal health plan |
| Mental retardation |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| Mental retardation screening |
Intellectual disability screening |
| Mental/developmental handicap screening |
Screening for developmental disorder (procedure) |
| Mental/developmental handicap screening NOS |
Screening for developmental disorder (procedure) |
| Mental/developmental handicap screening NOS |
Screening for developmental disorder (procedure) |
| Menthol 35.55mg inhalant capsule |
Product containing only menthol in pulmonary dose form (medicinal product form) |
| Mepacrine hydrochloride 100mg tablet |
Mepacrine hydrochloride 100 mg oral tablet |
| Meperidine hydrochloride 100mg/mL injection solution ampule |
Product containing only pethidine in parenteral dose form (medicinal product form) |
| Meperidine hydrochloride 50mg/5mL syrup |
Pethidine hydrochloride 10 mg/mL oral solution |
| Meperidine hydrochloride 50mg/mL injection solution ampule |
Product containing only pethidine in parenteral dose form (medicinal product form) |
| Meperidine hydrochloride 50mg/promethazine hydrochloride 50mg injection solution vial |
Product containing only pethidine and promethazine (medicinal product) |
| Mepivacaine hydrochloride 3%/levonordefrin 1:20,000 injection solution vial |
Corbadrine 50 microgram/mL and mepivacaine hydrochloride 30 mg/mL solution for injection |
| Mepivacaine hydrochloride 30mg/sodium chloride 3mg injection solution vial |
Mepivacaine only product |
| Mepivacaine hydrochloride+epinephrine 2%/1:100,000 cartridge |
Adrenaline 10 microgram/mL and mepivacaine hydrochloride 20 mg/mL solution for injection |
| Mepivacaine hydrochloride+epinephrine 2%/1:100,000 cartridge |
Adrenaline 10 microgram/mL and mepivacaine hydrochloride 20 mg/mL solution for injection |
| Meptazinol 100mg/1mL injection |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Meptazinol 100mg/mL injection solution 1mL ampule |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Meptazinol 200mg tablet |
Meptazinol (as meptazinol hydrochloride) 200 mg oral tablet |
| Mercurophylline injection |
Mercurophylline |
| Merselene patch |
Polyester mesh (physical object) |
| Mesalamine 250mg capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 250mg m/r capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 250mg prolonged-release oral capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 375mg m/r capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 375mg prolonged-release oral capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine 1g/100mL retention enema |
Mesalazine only product in rectal dose form |
| Mesalazine 1g/100mL retention enema |
Mesalazine only product in rectal dose form |
| Mesalazine 2g/59mL enema |
Mesalazine only product in rectal dose form |
| Mesalazine 500mg/sachet gastro-resistant and prolonged-release oral granules |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine 500mg/sachet m/r granules |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine duplicate deleted |
Product containing mesalazine (medicinal product) |
| Mesenteric venous thrombosis |
Thrombosis of mesenteric vein |
| Mesio-occlusion |
Mesio-occlusion of teeth |
| Mesonephric tumor |
Wolffian tumor of uncertain behavior (morphologic abnormality) |
| Mesoridazine besylate 10mg/mL injection solution ampule |
Product containing precisely mesoridazine 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mesoridazine besylate 25mg/mL injection solution ampule |
Product containing precisely mesoridazine 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mesothelioma, biphasic, benign |
Mesothelioma, benign |
| Metabolic acidosis caused by ingestion of drugs AND/OR chemicals |
Metabolic acidosis |
| Metabolic disease, NEC |
Metabolic disease |
| Metabolic marker |
Inborn errors of metabolism marker |
| Metacarpal X-ray |
Plain X-ray of metacarpal bone |
| Metacarpal X-ray |
Plain X-ray of metacarpal bone |
| Metacarpal X-ray |
Plain X-ray of metacarpal bone |
| Metaiodobenzylguanidine[123I] 74MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[123I] 74MBq/mL powder for injection solution vial |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I] 37MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I] 37MBq/mL powder for injection solution vial |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]370MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]37MBq/mL diagnostic injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]9.25MBq/mL diagnostic injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metallocarboxypeptidase |
Metallocarboxypeptidase |
| Metalloproteinase |
Metalloproteinase (substance) |
| Metaproterenol 20mg tablet |
Orciprenaline sulfate 20 mg oral tablet |
FHIR